华润医药(03320.HK) 宣布,集团旗下“昆明贝克诺顿”申报的3类仿制药“吗替麦考酚酯干混悬剂”获批生产并视同过评。 据介绍,“吗替麦考酚酯干混悬剂”为国家医保乙类品种,适用于接受同种异体肾脏或肝脏移植的患者中预防器官的排斥反应,也可用于狼疮性肾炎患者的诱导期治疗和维持期治疗。(hc/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-21 16:25。)AASTOCKS新闻
Source Link华润医药(03320.HK) 宣布,集团旗下“昆明贝克诺顿”申报的3类仿制药“吗替麦考酚酯干混悬剂”获批生产并视同过评。 据介绍,“吗替麦考酚酯干混悬剂”为国家医保乙类品种,适用于接受同种异体肾脏或肝脏移植的患者中预防器官的排斥反应,也可用于狼疮性肾炎患者的诱导期治疗和维持期治疗。(hc/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-21 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.